Medical is one of the seven sectors in the S&P 500 cohort that is expected to register earnings growth in the second quarter. As per the latest Zacks Earnings Trend report, overall second-quarter earnings for S&P 500 companies are expected to be down 3.6% (slightly better than the earlier estimated decline of 5.4%) from the year-ago quarter on revenues that are estimated to decline 0.5%.
Notably, 103 S&P companies have released their quarterly numbers so far, dissipating the gloom cast by the forecasts issued at the onset of the earnings season, thanks to the lower estimates.
Earnings for these companies are down 2.1% year over year on revenue growth of 1.4%. Notably, 68.9% has beaten EPS estimates while 56.3% managed to clock a beat.
On the other hand, Medical is estimated to report earnings growth of 1.7% on revenue improvement of 7.7%. Medical product is an important component of the medical sector and is expected to follow the same earnings growth trajectory in the quarter.
Here are two medical product companies lined up to report earnings on Jul 25.
After market close, CryoLife Inc is scheduled to release its quarterly numbers. Strong momentum at the company’s tissue processing BioGlue business and a string of strategic initiatives are key growth drivers.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of Zacks Rank #2 (Buy) and Earnings ESP of 0.00% (read more: Can CryoLife Earnings Spring a Surprise in Q2?).
That is because, as per our model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) to beat earnings. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Vascular Solutions Inc. offers the Vascular Solutions Duett sealing device which allows cardiologists and radiologists to rapidly seal the puncture site following catheterization procedures such as angiography, angioplasty and stenting.
The company’s strong pipeline of products (40 new ideas at various stages of development), solid growth prospects for most of the existing products and improved manufacturing efficiencies are expected to drive substantial growth.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #3 and Earnings ESP of 0.00%.
We also note that Vascular Solutions’ results compared favorably with the Zacks Consensus Estimate in the last four quarters, with an average beat of 13.73%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Image: Bigstock
Medical Product Stocks Jul 25 Earnings Roster: CRY, VASC
Medical is one of the seven sectors in the S&P 500 cohort that is expected to register earnings growth in the second quarter. As per the latest Zacks Earnings Trend report, overall second-quarter earnings for S&P 500 companies are expected to be down 3.6% (slightly better than the earlier estimated decline of 5.4%) from the year-ago quarter on revenues that are estimated to decline 0.5%.
Notably, 103 S&P companies have released their quarterly numbers so far, dissipating the gloom cast by the forecasts issued at the onset of the earnings season, thanks to the lower estimates.
Earnings for these companies are down 2.1% year over year on revenue growth of 1.4%. Notably, 68.9% has beaten EPS estimates while 56.3% managed to clock a beat.
On the other hand, Medical is estimated to report earnings growth of 1.7% on revenue improvement of 7.7%. Medical product is an important component of the medical sector and is expected to follow the same earnings growth trajectory in the quarter.
Here are two medical product companies lined up to report earnings on Jul 25.
After market close, CryoLife Inc is scheduled to release its quarterly numbers. Strong momentum at the company’s tissue processing BioGlue business and a string of strategic initiatives are key growth drivers.
CRYOLIFE INC Price and EPS Surprise
CRYOLIFE INC Price and EPS Surprise | CRYOLIFE INC Quote
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of Zacks Rank #2 (Buy) and Earnings ESP of 0.00% (read more: Can CryoLife Earnings Spring a Surprise in Q2?).
That is because, as per our model, a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 or 3 (Hold) to beat earnings. Simultaneously, we caution against stocks with a Zacks Rank #4 or 5 (Sell rated) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Vascular Solutions Inc. offers the Vascular Solutions Duett sealing device which allows cardiologists and radiologists to rapidly seal the puncture site following catheterization procedures such as angiography, angioplasty and stenting.
VASCULAR SOLUTN Price and Consensus
VASCULAR SOLUTN Price and Consensus | VASCULAR SOLUTN Quote
The company’s strong pipeline of products (40 new ideas at various stages of development), solid growth prospects for most of the existing products and improved manufacturing efficiencies are expected to drive substantial growth.
However, our proven model does not conclusively show that the company is likely to beat earnings, given the combination of a Zacks Rank #3 and Earnings ESP of 0.00%.
We also note that Vascular Solutions’ results compared favorably with the Zacks Consensus Estimate in the last four quarters, with an average beat of 13.73%.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>